Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 408 - 408

Published: March 13, 2025

Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.

Language: Английский

---

Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study

Clinical Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: July 24, 2024

Abstract Background Semaglutide is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight and may have consequences on function. Methods This a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally HIV/AIDS Other Infections, ACTG A5371) study, single-arm study semaglutide in people with human immunodeficiency virus (HIV, PWH) metabolic dysfunction–associated steatotic liver diseases (MASLD). Participants received subcutaneous 24 weeks (titrated to 1 mg/week by week 4). Psoas volume fat fraction were assessed magnetic resonance imaging, physical function was 10-time chair rise test 4 m gait speed. Mean change baseline estimated linear regression modeling. Results Fifty-one PWH enrolled (muscle measures n = 46). The mean age 50 years (standard deviation, 11), body index 35.5 kg/m2 (5.6), 43% women, 33% Black, 39% Hispanic/Latino. decreased 9.3% (95% confidence interval [CI]: −13.4 −5.2; P < .001) over weeks, but psoas did not significantly (−0.42%; 95% CI: −1.00 .17; .16). Chair speed showed nonsignificant improvements 1.27 seconds −2.7 .10) 0.05 m/sec −.01 .10), respectively (both > .07). prevalence slow (<1 m/sec) 63% 46% (P .029). Conclusions In receiving MASLD, despite volume, there no significant function, suggesting maintained muscle. Trials Registration NCT04216589.

Language: Английский

---

Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma

Pituitary, Journal Year: 2024, Volume and Issue: 27(5), P. 723 - 730

Published: Aug. 1, 2024

Abstract Purpose Patients with hypothalamic pathology often develop obesity, causing severe metabolic alterations resulting in increased morbidity and mortality. Treatments for obesity have not proven very effective, although the glucagon-like peptide-1 receptor agonist semaglutide has been shown to positive effects. We examined semaglutide’s effect on weight loss a sample of patients obesity. Methods Four female from treatment craniopharyngiomas were treated six months. Whole Body Dual-energy x-ray absorptiometry scans performed, blood samples drawn at baseline after Semaglutide dosages monthly along tracking body eating behavior (Three Factor Eating Questionnaire, TFEQ-R18). Results BMI was reduced all cases, an average 7.9 (range: 6.7 10.1) corresponding 17.0% 11.3–22.4%) or 20.2 kg (range 16.2 23.4 kg). found comparable reduction total fat mass (17.2%, p = 0.006) lean (16.0%, 0.05), whereas bone unchanged (2.6%, 0.12). All cases reported increase energy levels, improved mobility physical activity. Unfavorable behaviors 1 month (emotional − 41 points, 0.02, uncontrolled 23 0.11). HbA1c cholesterol significantly ( 0.014 both). Conclusion is promising safe option HO, that improves behavior, reduces weight, markers.

Language: Английский

---

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: July 23, 2024

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss

Language: Английский

---

Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management

Nutrients, Journal Year: 2024, Volume and Issue: 16(24), P. 4407 - 4407

Published: Dec. 23, 2024

Background: Anabolic resistance accelerates muscle loss in aging and obesity, thus predisposing to sarcopenic obesity. Methods: In this retrospective analysis of a randomized clinical trial, we examined baseline predictors the adaptive response three months home-based exercise, daily physical activity, protein-based, multi-ingredient supplementation (MIS) cohort free-living, older males (n = 32). Results: Multiple linear regression analyses revealed that obesity Global Risk Index for metabolic syndrome (MetS) were strongest Δ% gains lean mass (TLM ASM), LM/body fat ratios (TLM/%BF, ASM/FM, ASM/%BF), allometric LM (ASMI, TLM/BW, TLM/BMI, ASM/BW), with moderately strong, negative correlations polytherapy r −0.36 −0.68 (p < 0.05). Kidney function, PA level, chronological age only weakly associated treatment outcomes > Next, performed subgroup overweight/obese participants at least one other MetS risk factor their two types protein-based MIS (PLA; collagen peptides safflower oil, n 8, M5; whey/casein, creatine, calcium, vitamin D3, fish 12). The M5 group showed greater improvements (ASM; +2% vs. −0.8%), (ASM/FM; +3.8% −5.1%), (ASM/BMI; +1.2% −2.5%), strength (leg press; +17% −1.4%), performance (4-Step-Stair-Climb time; −10.5% +1.1%) PLA Bone turnover markers, indicative bone accretion, increased pre-to-post intervention (P1NP; p 0.036, P1NP/CTX ratio; 0.088). overall anabolic response, as indicated by ranking low-to-high responders 0.0079), 0.097), 0.19), was therefore significantly higher 0.013). Conclusions: Our findings confirm obesity/MetS is key driver old high-quality, whey/casein-based more effective than collagen-based alternative maintaining musculoskeletal health individuals even when total protein intake exceeds current guidelines.

Language: Английский

---

MuSK-BMP signaling in adult muscle stem cells maintains quiescence and regulates myofiber size

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: May 18, 2023

SUMMARY A central question in adult stem cell biology is elucidating the signaling pathways regulating their dynamics and function diverse physiological age-related contexts. Muscle cells adults (Satellite Cells; SCs) are generally quiescent but can activate contribute to muscle repair growth. Here we tested role of MuSK-BMP pathway SC quiescence by deletion BMP-binding MuSK Ig3 domain (‘ΔIg3-MuSK’). At 3 months age myonuclei numbers myofiber size were comparable WT. However, at 5 density was decreased while size, myonuclear number grip strength increased - indicating that SCs had activated productively fused into myofibers over this interval. Transcriptomic analysis showed from uninjured ΔIg3-MuSK mice exhibit signatures activation. Regeneration experiments maintain full function. Expression sufficient break increase size. We conclude regulates a autonomous, age-dependent manner. Targeting thus emerges therapeutic strategy for promoting growth settings injury, disease, aging. Highlights MuSK, its as BMP co-receptor, The acts autonomously Increased with preservation stemness attenuated

Language: Английский

---

Beyond fat: Does semaglutide affect lean mass?

Clinical Nutrition, Journal Year: 2024, Volume and Issue: 44, P. 104 - 108

Published: Dec. 4, 2024

Language: Английский

---

Evolutionary Mismatch and Lifestyle‐Related Diseases: A Study of a 6‐Month Intensive Lifestyle Intervention

Scandinavian Journal of Medicine and Science in Sports, Journal Year: 2024, Volume and Issue: 34(12)

Published: Dec. 1, 2024

Chronic medical conditions caused by the inadequate adaptation of body to modern lifestyles, such as physical inactivity and unhealthy diets, are on rise. This study assessed whether a comprehensive lifestyle intervention, including high volumes supervised exercise, could improve health outcomes. Eight volunteers with lifestyle-related diseases received 6-month intervention consisting 8000-10 000 steps/day, 6 moderate-intensity endurance 3 resistance training sessions per week, 5-week long hike, dietary advice. was followed 7 months limited remote supervision, ending 13 from baseline. The participants (3 females, 5 males; mean age 42.9 years) had type 2 diabetes (T2D), depression/stress, metabolic syndrome (MS). After months, weight decreased significantly 23 kg (95% CI; -33.7 -12.2), minor non-significant decrease in lean mass 1.96 -4.34 0.27). Maximal oxygen consumption (VO

Language: Английский

---

Spotlight on the Mechanism of Action of Semaglutide

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(12), P. 14514 - 14541

Published: Dec. 23, 2024

Initially intended to control blood glucose levels in patients with type 2 diabetes, semaglutide, a potent glucagon-like peptide 1 analogue, has been established as an effective weight loss treatment by controlling appetite. Integrating the latest clinical trials, semaglutide or without diabetes presents significant therapeutic efficacy ameliorating cardiometabolic risk factors and physical functioning, independent of body reduction. Semaglutide may modulate adipose tissue browning, which enhances human metabolism exhibits possible benefits skeletal muscle degeneration, accelerated obesity ageing. This be attributed anti-inflammatory, mitochondrial biogenesis, antioxidant autophagy-regulating effects. However, most supporting evidence on mechanistic actions is preclinical, demonstrated rodents not actually confirmed humans, therefore warranting caution interpretation. article aims explore potential innovative molecular mechanisms action restoring balance several interlinking aspects metabolism, pointing distinct functions inflammation oxidative stress insulin-sensitive musculoskeletal tissues. Moreover, applications protection from infections anti-aging properties are discussed. enhancement core involved progress although mostly provide framework for future research diseases overall.

Language: Английский

---

Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS

Heart Failure Reviews, Journal Year: 2024, Volume and Issue: 29(5), P. 939 - 944

Published: July 4, 2024

Language: Английский

---